The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers-Reference-Cited by-同舟云学术

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

Published:2012-06 Issue:7404 Volume:486 Page:537-540
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Diaz Jr Luis A.,Williams Richard T.,Wu Jian,Kinde Isaac,Hecht J. Randolph,Berlin Jordan,Allen Benjamin,Bozic Ivana,Reiter Johannes G.,Nowak Martin A.,Kinzler Kenneth W.,Oliner Kelly S.,Vogelstein Bert

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature11219.pdf

Reference28 articles.

1. Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626–1634 (2008)

2. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765 (2008)

3. Pao, W. et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, e17 (2005)

4. Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–1043 (2007)

5. Corcoran, R. B. et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal. 3, ra84 (2010)

Cited by 1458 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic Reversal of Drug Resistance in Cancer;Targets;2024-09-13

2. Analysis of urine cell-free DNA in bladder cancer diagnosis by emerging bioactive technologies and materials;Frontiers in Bioengineering and Biotechnology;2024-09-04

3. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities;Nature Reviews Cancer;2024-09-02

4. The Impact of Liquid Biopsy in Advanced Ovarian Cancer Care;Diagnostics;2024-08-26

5. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24